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Chronic obstructive pulmonary disease (COPD) is a progressive lung disease 
characterized by expiratory flow limitation. The knowledge about factors contributing 
to the long-term changes in exercise capacity and breathing pattern in terms of the 
relationship between tidal volume (VT) and minute ventilation (V̇E) in COPD is 
scarce. This thesis deals with issues related to long-term changes in exercise capacity 
and breathing pattern in COPD and potential predictors for the changes. The thesis is 
based on three studies. 
Study I was a 3-years prospective cohort study, including 389 patients with COPD in 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II-IV. We 
examined predictors for the longitudinal change in six-minute walking distance 
(6MWD). Study II was a cross-sectional study, including 63 COPD patients 
performing a cardiopulmonary exercise test (CPET) on treadmill. We aimed to study 
if a quadratic equation (VT = a + b·V̇E + c· V̇E2) could describe the breathing pattern 
in terms of the relationship between V̇E and VT during incremental exercise in COPD. 
Study III was a longitudinal cohort study, were the 63 COPD patients performed two 
CPETs with a mean time of 4.5 years between the tests. The longitudinal changes in 
peak oxygen uptake (V̇O2peak) and breathing pattern as well as potential explanatory 
variables of change were examined. 
The 6MWD decreased significantly during the observation period in GOLD stage III 
(B= −36, 95 % Confidence Interval (CI): -51 to -7, p=0.009) and IV (B= −79, 95 % 
CI: −125 to −20, p=0.007), while patients in GOLD stage II maintained their walking 
distance. Predictors for the longitudinal change in 6MWD were self-reported hard 
physical activity and FEV1. The fraction of subjects performing hard physical activity 
at three years was higher in those who had participated in a pulmonary rehabilitation 
program during the observation period, odds ratio 2.4 (95 % CI 1.4−4.2, p=0.001). 
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In Study II we found that a quadratic model could describe the relationship between 
V̇E and VT in 59 of 63 COPD patients (p<0.05) and the linear coefficient (b) was 
negatively (p=0.001) and the quadratic coefficient (c) positively (p<0.001) related to 
FEV1. 
In Study III, V̇O2peak and FEV1 deteriorated significantly during follow-up. The 
reduction in V̇O2peak was related to baseline V̇O2peak (p<0.001), the changes in resting 
inspiratory capacity (IC) (p=0.005) and FEV1 (p=0.031), age (p=0.023) and smoking 
during follow-up (p=0.021). A higher baseline V̇O2peak, a larger decrease in IC and 
FEV1 and higher age were associated with a larger reduction in V̇O2peak. The 
quadratic model described the relationship between V̇E and VT in 61 of 63 patients at 
CPET1 and at 59 of 63 patients at CPET2. The linear coefficient (b) increased 
(p=0.007) and the quadratic coefficient decreased significantly (p=0.002) from 
CPET1 to CPET2. Maximal VT was achieved at a lower V̇E. The changes in the curve 
parameters were all related to the change in FEV1.  
We have concluded that exercise capacity deteriorates over time in COPD, and that 
the longitudinal change is related to the decline in lung function. Persistent smoking is 
associated with a larger decline, while high habitual physical activity is associated 
with a lower decline in exercise capacity. The longitudinal change in breathing pattern 
is associated with the reduction in lung function. Any relationships between 
exertional dyspnea and changes in breathing pattern need further studies.  
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Chronic obstructive pulmonary disease (COPD) is a progressive lung disease 
characterized by expiratory flow limitation (1), and is a leading cause of mortality and 
morbidity worldwide (2, 3). The prevalence of the disease is expected to increase in 
the coming decades (3) and the economic and social burden is substantial and 
increasing (2, 3). COPD accounts for a significant portion of the costs of health care 
in high income countries (4, 5) and there is a relationship between the disease severity 
and the cost of care (1).  
Dyspnea is usually the major symptom in patients with COPD, and is defined as “a 
subjective experience of breathing discomfort that consists of qualitatively distinct 
sensation that varies in intensity” (6). The individual’s sensation of dyspnea is related 
to the reduction in breathing capacity, which in turn is related to the volume of each 
breath and breathing frequency (7-9).  Dyspnea is frequently the cause of exercise 
limitation (8, 10-12), leading to inactivity and reduced participation in activities of 
daily living (13, 14). During the time course of COPD, the disease severity usually 
progresses with further deterioration of lung function (15, 16) and reduced exercise 
capacity (17-19).  
The knowledge about factors contributing to long-term changes in exercise capacity 
and ventilatory capacity, including breathing pattern in terms of the relationship 
between tidal volume and ventilation is scarce in patients with COPD. The objectives 
of the present thesis were therefore to examine long-term changes in exercise capacity 
and breathing pattern in patients with COPD and to examine potential predictors for 
the changes. These questions were addressed in the three studies of the present thesis. 
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1.1 Chronic obstructive pulmonary disease (COPD) 
1.1.1 Definition 
The Global Iniative for Chronic Obstructive Lung Disease (GOLD) has defined 
COPD in the following way: “a common preventable and treatable disease, is 
characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response in the airways and the 
lung to noxious particles or gases. Exacerbations and comorbidities contribute to the 
overall severity in indivdual patients” (1). 
COPD is not curable, and known risk factors for developing the disease are cigarette 
smoking and occupational and environmental exposures including dusts and 
chemicals (1).  
 
1.1.2 Epidemiology  
COPD is today the fourth leading cause of death worldwide (20) and the burden of 
COPD is expected to increase in the coming decades. In 2030 COPD is predicted to 
be the third leading cause of death (20). The prevalence of COPD is estimated to be 
around 9-10 % in the population older than 40 years in the Western world (21), with 
variations between countries and across different groups within countries (1). In 
Norway the prevalence is around 7-10 % (22, 23). There are variations in the 
prevalence estimates due to differences in diagnostic criteria, survey methods, and 
analytic methods (21). Still COPD may be largely undiagnosed (24-26), because some 
persons may have major reduction in lung function before they experience that the 
symptoms are limiting their participation in activities of daily living (1). 
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1.1.3 Diagnosis  
COPD is characterized by irreversible airflow limitation with permanently reduced 
lung function (1). Airflow limitation is assessed with spirometry measuring the forced 
vital capacity (FVC) which is the total volume of gas that can be expired from total 
lung capacity (TLC) with maximal effort. Forced expiratory volume in one second 
(FEV1) is the volume of gas expired in the first second (27). FEV1 and the FEV1/FVC 
ratio are related to the maximal expiratory flow rates during the forced expiratory 
manoeuver, and FEV1 and FEV1/FVC ratio are used to evaluate the severity of airflow 
limitation (27). COPD is categorized into four stages according to the GOLD-2007 
classification (1) (Table 1). The common criterion for all categories is a post 
bronchodilator FEV1/FVC < 0.70, and the severity is increasing with an increasing 
reduction in FEV1.  
Table 1. The GOLD-2007 classification of COPD  
Classification of severity of airflow limitation in COPD 
(Based on post bronchodilator FEV1) 
GOLD 1: Mild  FEV1/FVC < 0.70 
FEV1 ≥ 80 % predicted 
GOLD 2: Moderate  FEV1/FVC < 0.70 
50 % ≤ FEV1 < 80 % predicted 
GOLD 3: Severe  FEV1/FVC < 0.70 
30 % ≤ FEV1 ≤ 50 % predicted 
GOLD 4: Very severe  FEV1/FVC < 0.70 
FEV1 < 30 % predicted 
GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV1:  
Forced Expiratory Volume in one second; FVC: Forced Vital Capacity 
With permission from the Global Strategy for Diagnosis, Management and Prevention of COPD 2015, © 
Global Initiative for Chronic Obstructive Lung Disease (GOLD), all rights reserved. Available from 
http://www.goldcopd.org.  
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Since the GOLD classification (staging) system was first presented in 2001, the 
knowledge about COPD and its extrapulmonary features has increased. The original 
guideline was based on FEV1, because at that time, it was believed that the disease 
severity was tracked by the severity of airflow obstruction in the majority of patients 
(1). The use of FEV1/FVC < 0.7 ratio to define airflow limitation has resulted in more 
frequent diagnosis of COPD in the elderly (28) and less in adults younger than 45 
years (29).  
In 2011 the GOLD Scientific committee presented a new approach for clinical 
grading of COPD (Figure 1) (1). The disease severity was determined by assessing 
airflow limitation, the impact on the patient’s health status, and the frequency of 
exacerbations and hospital admission. The superiority of the new 2011 GOLD 
classification compared with the GOLD-2007 classification still needs to be 
established. In a study by Johannessen et al. (30) a comparison between GOLD- 2011 
and GOLD- 2007 in terms of predicting mortality and hospitalization was examined. 
They concluded that the predictive power between these two did not differ 
significantly.  
Exacerbation of COPD is defined as worsening of the patient’s respiratory symptoms 
beyond normal day to day variation which may lead to a change in medication (31-
33).  Exacerbations have negative influence on quality of life in the individual patient 
(32, 34). The recovery time after exacerbations regarding symptoms and lung function 
can be several weeks, and lung function may show a permanent decline after recovery 
(35, 36). Exacerbations in COPD are associated with mortality and have high 
socioeconomic costs (37). 
Patients with COPD often have other coexisting diseases (comorbidities) (1). These 
diseases can either occur independently of COPD or be causally related. Comorbidity 
can occur regardless of disease severity. The most common comorbidities in COPD 
are cardiovascular disease, hypertension, osteoporosis, lung cancer, infections 
(especially respiratory infections), bronchiectasis, anxiety and depression. 
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The combined COPD assessment (1) including symptom scores, breathlessness, 
spirometric classification and exacerbation history is illustrated in Figure 1.  
 
Figure 1. Assessment of COPD with risk factors according to the GOLD grading 
system including assessment of symptoms, breathlessness, spirometric classification 
and exacerbations history.  
mMRC: Modified British Medical Research Council; CAT: COPD Assessment Test  
With permission from the Global Strategy for Diagnosis, Management and Prevention of COPD 2015, © 
Global Initiative for Chronic Obstructive Lung Disease (GOLD), all rights reserved. Available from 
http://www.goldcopd.org.  
 
Another multidimensional grading system developed to assess respiratory and 
systemic expression of COPD is the BODE index, which includes the body-mass 
index (B), the degree of airflow obstruction (O), dyspnea (D) and exercise capacity 
(E) measured by the 6-minute walk test (38). The BODE index has been shown to be 
better than FEV1 alone to predict risk of death (38). 
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1.1.4 Management  
The management of COPD can be divided into pharmacologic and non-
pharmacologic treatment (1). The recommended non-pharmacologic treatment 
includes smoking cessation, pulmonary rehabilitation, exercise training, physical 
activity and oxygen therapy (1).   
 
Smoking cessation 
Cigarette smoking is identified as the most common risk factor for COPD, and 
smoking cessation is the intervention that with greatest significance can influence the 
natural development of COPD. Pharmacotherapies for smoking cessation are nicotine 
replacement products that have shown to decrease the long-term abstinence better 
than placebo (39-41).  
The most important intervention for all patients with COPD, who still smoke, 
regardless of disease severity, should therefore be smoking cessation (1). 
 
Pulmonary rehabilitation 
The definition of pulmonary rehabilitation according to American Thoracic Society 
(ATS) and European Respiratory Society (ERS) Statement is as follows (14): 
“Pulmonary rehabilitation is a comprehensive intervention based on a thorough 
patient assessment followed by patient-tailored therapies that include, but are not 
limited to, exercise training, education and behavior change, designed to improve the 
physical and psychological condition of people with chronic respiratory disease and 
to promote the long-term adherence to health-enhancing behavior.”   
A pulmonary rehabilitation program includes a combination of education, exercise 
training and strategies for behavioral change. It is recommended that treatment should 
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be tailored to the individual patient’s need, based on initial and ongoing assessments 
according to disease severity, comorbidities and complexity (13, 14).  
The settings for pulmonary rehabilitation as described in the ATS/ERS Statement (14) 
can be conducted in inpatient and outpatient settings. Outpatient settings can include 
outpatient clinics at hospitals, community facilities and physiotherapy clinics. 
Inpatient rehabilitation can find place at rehabilitation departments at hospitals, or 
during inpatient acute care, for example at intensive care units (14). In addition, 
exercise training can also be provided in the patient’s home. 
There is no consensus about the optimal duration of pulmonary rehabilitation 
programs (19). However, longer programs are considered to provide greater gains and 
benefits, and a minimum of 8 weeks is recommended (42-44). Programs longer than 
12 weeks have shown greater benefits than shorter programs (43, 45, 46). The number 
of sessions per week in a pulmonary rehabilitation program varies, but two or three 
days per week are common in outpatient settings, while five days per week is 
common in inpatients settings (47, 48). 
 
Exercise training 
Exercise training is considered as the cornerstone in a pulmonary rehabilitation 
program, but what is the distinction between physical activity and exercise? These 
terms describe different concepts, but are often used interchangeably. Physical 
activity is defined as “any bodily movement produced by skeletal muscles that result 
in energy expenditure” (49). Physical activity in daily life can be categorized as 
household, sports, conditioning, occupational or other activities. Exercise is defined 
as “a subset of physical activity that is planned, structured, and repetitive and has a 
final or an intermediate objective of the improvement or maintenance of physical 
fitness” (49).  
Exercise training does not improve lung function or gas exchange (50), but improves 
the function of other body systems so the effect of reduced lung function is 
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minimized. Gains from exercise training are increased exercise tolerance, reduced 
dyspnea and increased health-related quality of life (51). The deconditioned skeletal-
muscle function is improved by exercise training as a result of changes in muscle 
biochemistry; higher work rates can be tolerated without substantial lactic acidosis 
(52). The sensation of dyspnea is improved after pulmonary rehabilitation, because 
exercise training and breathing techniques reduce the ventilatory requirement and 
respiratory rate, prolonging the time for expiration and thereby reducing dynamic 
hyperinflation (53).  
Exercise training in a pulmonary rehabilitation program should, according to the 
ATS/ERS Statement (14), consist of a combination of endurance and resistance (or 
strength) training. The endurance training can either be continuous or interval based. 
Interval training consists of periods with high intensity exercise alternated with 
periods of low intensity exercise. Interval training may show to result in lower 
symptom scores (54), but not at the cost of the effects of the training (54-56). 
However, previous studies have not found any clinically important differences in 
effect between interval and continuous training regarding exercise capacity, health-
related quality of life, and improvements in skeletal muscles (55, 57-62), and these 
training modalities appear to be equally effective. In symptom-limited patients who 




Breathing techniques are often a part of pulmonary rehabilitation program (63) and 
focus on slowing the respiratory rate, primarily by prolonging the expiration. This can 
be useful in reducing dyspnea in patients having dynamic hyperinflation (64). 
Different breathing strategies can be pursed-lips breathing (65), yoga breathing and 
computer-aided breathing feedback (66). Patients who undergo breathing training 
have shown an adaptation to a slower and deeper pattern of breathing (66). Pursed-
24 
lips breathing have reduced dyspnea after a walk test (65), and computer-aided 
breathing feedback has shown reduced dynamic hyperinflation (65).  
Decreased anxiety and depression are also demonstrated after pulmonary 
rehabilitation, and are thought to occur as a consequence of increased exercise 
capacity, increased activities of daily living and in turn increased experience of 
mastering (51). 
In patients with COPD, the short-term effect of pulmonary rehabilitation has 
demonstrated a reduction in dyspnea, increased exercise capacity and improved 
quality of life (13). Without any strategies to maintain benefits after pulmonary 
rehabilitation, the effects seem to diminish after 6-12 months, with quality of life 
being better maintained than exercise capacity (67-69). 
 
Physical activity  
Daily physical activity is recommended for all patients with COPD (70), however, 
research evidence that support this recommendation is scarce. Physical inactivity is 
common in these patients and found to be associated with poor outcomes, 
independent of the degree of reduced lung function (71). Activity monitors have been 
developed to measure activity, and are increasingly being included to quantify activity 
in pulmonary rehabilitation (70). 
 
Oxygen therapy 
Long-term oxygen treatment (>15 hours per day) is indicated in patients who have a 
resting partial pressure of arterial oxygen (PaO2) below 7.3 kPa or arterial oxygen 
saturation (SaO2) values of 88 % or lower with or without hypercapnia. These 
measurements have to be confirmed twice over a period of three weeks (1). Another 
indication for long-term oxygen treatment can be PaO2 between 7.3 and 8.0 kPa, or 
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SaO2 of 88 %, if there is pulmonal hypertension, cardiac failure or polycythemia (1). 
A decision about this treatment should be based on resting PaO2 or SaO2 in stable 
patients (1).  
 
Pharmacologic treatment 
In stable COPD, pharmacologic treatment is used to improve lung function and to 
reduce symptoms, improve health status, improve exercise tolerance, and reduce the 
frequency and number of exacerbations (1, 13, 51). The overall goal is to optimize the 
medical treatment to the individual patient using the GOLD-2011 grading assessment 
as a guideline (1). However, the existing medications for COPD have not 
conclusively demonstrated attenuation of the long-term deterioration in lung function 
(72-75).  
 
1.2 Patophysiology and exercise limitation in COPD 
The cause of exercise intolerance in patients with COPD is multifactorial and related 
to disease severity. Contributing factors can be, either alone or in combination, 
ventilatory constraints, dyspnea, development of dynamic hyperinflation, gas 
exchange abnormalities, cardiac limitation and peripheral and respiratory muscle 
dysfunction (76-78).  
 
1.2.1 Pathophysiology 
COPD is characterized by persistent airway limitation. Maximal expiratory flow rates 
are determined by airway diameter and compliance of the airway wall (79), and FEV1 
is the integrated sum of maximal expiratory flow rates in the first second (80). 
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Chronic inflammatory processes contribute to loss of elastic tissue in the lung 
parenchyma (81). The mechanical support of the airway walls is reduced, increasing 
the compliance and thereby the airways are more prone to collapse (81, 82). 
Furthermore, loss of elastic tissue in the lung parenchyma increases lung compliance 
and lung elastic recoil is reduced (82). Over time, the destruction of lung parenchyma 
lead to loss of alveolar surface area and reduced gas exchange capacity (82).  
The functional residual capacity (FRC) and closing volume will increase due to 
reduced lung elastic recoil and increased airway collapsibility (83). Lung 
hyperinflation is defined as increased FRC or end-expiratory lung volume (EELV) 
above the normal (83). EELV is the volume air remaining in the lungs after a 
spontaneous expiration (84, 85). FRC is the equilibrium volume of the lung and chest. 
FRC and EELV are normally equal with resting breathing, but not with increased 
ventilatory demands. In normal subjects EELV becomes lower than FRC during 
exercise (84, 85).  
Patients with COPD can have hyperinflated lungs at rest (static hyperinflation) and 
increasing EELV in response to progressively increasing exercise load and ventilatory 
demand (dynamic hyperinflation) (86). Hyperinflation in COPD has been shown to 
contribute to the sensation of dyspnea (87) and morbidity (88). An increased end-
inspiratory lung volume (EILV) has been shown to increase the sensation to dyspnea 
and reduce exercise capacity (10, 89).  A critically low inspiratory reserve volume 
(IRV) defined as a reduction in IRV around 0.5 L or below 10 % of TLC, has also 
found to be related to increased dyspnea (7, 9). 
 
1.2.2 Ventilatory limitation and dynamic hyperinflation  
The minute ventilation (V̇E) is the product of the tidal volume (VT) and the breathing 
frequency (Bf) (90, 91). At a given V̇E, the VT is lower and the Bf is higher in patients 
with COPD compared to healthy subjects, which means that dead space ventilation is 
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higher (92). Ventilatory capacity or maximal V̇E is related to maximal expiratory flow 
rates and FEV1 (92). A breathing reserve less than 15 % is considered as a ventilatory 
limitation (93).  
The maximal VT during exercise is typically about 50% of the vital capacity (94). 
There is a mechanical constraint on the inspiratory side because of the pressure-
volume characteristics of the lung and chest wall where the volume gain at some point 
will be low or minimal with respect to inspiratory effort. On the expiratory side, 
mechanical constraint on VT is the residual volume (RV), but with COPD the time 
constant of the lung is increased and the drive for the next inspiration may start before 
expiration is completed. Thus, there is a dynamic constraint on VT. The time constant 
is the product of resistance and compliance, both of which are increased in COPD 
(95). As a result, EELV increases and breathing takes place at a higher lung volume 
(dynamic hyperinflation) where both compliance and resistance are lower. The 
consequences for these compensatory mechanisms is a shorter time constant allowing 
complete breathing cycles, but it is at the cost of higher work of breathing (95, 96) 
and the sensation of dyspnea is increased. 
In patients with severe COPD, the VT during exercise increases quickly and reaches a 
critically low inspiratory reserve volume (IRV), or the VT plateau. This leads to a 
discrepancy between the effort of the respiratory muscle and the volume displacement 
achieved (9).  
 
Hyperinflation during exercise is illustrated in Figure 2. (97, 98) 
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Figure 2. Lung volumes and tidal pressure-volume curves during exercise in healty 
subjects and in patients with COPD.  
EELV: End-Expiratory Lung Volume; IC: Inspiratory Capacity; TLC: Total Lung Capacity; RV: 
Reidual Volume; IRV: Inspiratory Reserve Volume. 
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1.2.3 Gas exchange limitation 
The uptake of oxygen is described by the Fick’s equation: V̇O2 = Q̇ (CaO2 – Cv̅O2). 
V̇O2 is the oxygen consumption, Q̇ is cardiac output (CO), CaO2 is the oxygen 
concentration in arterial blood and Cv̅O2 is the oxygen concentration in the mixed 
venous blood entering the lungs. The oxygen uptake is proportional with the product 
of cardiac output and the arteriovenous oxygen difference. 
Oxygen is bound to hemoglobin, which is 97.5 % saturated at a partial pressure of 
oxygen (PO2) of about 13 kPa (99), and an increase in PO2 beyond 13 kPa increases 
the oxygen content in arterial blood by increasing the dissolved fraction only, which is 
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very low (99). At a lower PO2, the oxygen content of blood decreases abruptly about 8 
kPa as determined by the oxygen-hemoglobin dissociation curve. The oxygen 
concentration in arterial blood and pulmonary capillary blood is normally not very 
different unless the shunt fraction is increased. Gas transfer over the alveolocapillary 
membrane is by diffusion, and is dependent on the alveolar surface area, thickness of 
the membrane and the pressure difference of the gas over the membrane (99). In 
COPD, the number of alveoli is decreased and alveolar volume is increased resulting 
in a decreased alveolar surface area. The alveolar capillary blood volume is decreased 
(100). The ventilation – perfusion ratio (V̇/Q̇) gives the partial pressures of O2 and 
CO2 in a gas exchange unit. Units with a high V̇/Q̇ ratio will have a high PO2, but 
their contribution to the oxygen content in arterial blood is marginal since hemoglobin 
is saturated (100). These units contribute to increased alveolar dead space. Units with 
a low V̇/Q̇ ratio will have a low PO2, and may contribute to a substantial reduction in 
oxygen content in arterial blood (100). 
The efficiency of pulmonary gas exchange is judged by the extent of the alveolar-
arterial oxygen difference P(A – a)O2. Any gas diffusion limitation or V̇/Q̇ mismatch 
will result in a higher alveolar – arterial PO2 difference (100). Normally the PaO2 
does not decrease during exercise and P(A – a)O2 at peak exercise remains low. A 
P(A – a)O2 at peak exercise >4 kPa is defined as abnormal (101, 102) and is 
accompanied by arterial desaturation (103). 
Hypoxemia can limit exercise tolerance directly by increasing the pulmonary 
ventilation through augmenting chemoreceptor output and indirectly by increasing the 
production of lactic acid (104). During increasingly higher exercise intensity, 
anaerobic metabolism increases the lactic acid production and contributes to muscle 
task failure and increased ventilation (104). Supplemental oxygen therapy in patients 
with COPD, in both hypoxemic and non-hypoxemic patients, has shown to allow for 
higher exercise intensity. Possible explanations are decreased pulmonary arterial 
pressure, reduced lactic acid production and reduction in dynamic hyperinflation 
because of a reduction in respiratory rate (104-109). 
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1.2.4 Cardiac limitation 
CO is the product of heart rate (HR) and stroke volume (SV). HR increases linearly 
with V̇O2, and CO normally increases to a maximum of four to five times resting CO 
(110). The oxygen pulse is the ratio of V̇O2 to HR and is oxygen uptake per heartbeat. 
In fit individuals the oxygen pulse is higher at a given oxygen uptake because of 
higher SV, and it may be reduced in respiratory patients because of cardiac 
dysfunction. Maximum HR remains unchanged with fitness, but declines with 
increasing age, and an increased CO is due to an increment in SV (110). In respiratory 
patients, the peak HR is often less than predicted value because ventilatory limitation 
and dyspnea cause an interruption of the exercise before maximal values are reached. 
The heart rate reserve is usually high in COPD (93). 
The cardiovascular system can be affected by chronic lung disease due to increased 
right ventricular afterload which can result in hypertrophy of the right ventricle and 
right ventricular failure. Contributing factors to cardiovascular dysfunction during 
exercise can be hypoxic vasoconstriction (111), increased vascular resistance due to 
erythrocytosis (112), tachyarrhythmia and elevated right arterial pressure (113). 
 
1.2.5 Skeletal muscle dysfunction 
The skeletal muscles consist of two fiber types: type I and II. The type I (or slow-
twitch) fibers need a relatively long time to develop peak tension, mostly determined 
by its myosin-adenosine triphosphates (ATPase) (110). These fibers have high 
concentrations of oxidative enzymes, high mitochondrial content and high myoglobin 
concentration. Thus, the type I fibers are resistant to fatigue; the oxidative capacity is 
high and the glycolic capacity low. The type II (or fast switch) muscle fibers have 
relatively short time to peak tension, and have poor fatigue resistance and oxidative 
capacity, but have high glycolytic capacity. The type II fibers are classified into type 
IIa and type IIx. Type IIa fibers have high mitochondrial content and myoglobin 
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concentration and have some oxidative capacity, while the mitochondrial content and 
myoglobin concentration are low in type IIx fibers and there is little oxidative 
capacity (110). 
The recruitment of fiber types depends on the form of exercise. During low-intensity 
exercise mainly the type I fibers tend to be recruited, while type II fibers are recruited 
at higher intensity, at or above 70 % to 80 % of maximal aerobic power (114). 
Dysfunction of the lower limb muscles is a consequence of COPD and causes 
limitation in exercise capacity, physical activity, quality of life and morbidity (115-
117). Patients with COPD are often deconditioned as a result of inactivity, and muscle 
atrophy with reduced muscle strength is present. Lower quadriceps strength predicts 
mortality in COPD (116).  The lower limb cross-sectional area and capillarization are 
reduced, and loss of muscle fiber type I in favour of an increase in type IIx is reported 
(118-120). Thus, the aerobic muscle metabolism is reduced and production of lactic 
acidosis for a given exercise work rate increases the ventilatory needs. 
 
1.2.6 Respiratory muscle dysfunction 
In patients with COPD the respiratory muscles may be overloaded due to the 
increased work of breathing. The diaphragm has adapted to the chronic overload and 
has developed greater resistance to fatigue (121, 122). As a result, the inspiratory 
muscles in patients with COPD have shown to be capable of generating more pressure 
as compared to healthy subjects with identical lung volumes (123, 124). However, the 
respiratory muscles are placed at a mechanical disadvantage and despite the increased 
ability of the diaphragm to generate force; both inspiratory muscle strength (125) and 
endurance (126) are compromised. The respiratory muscle dysfunction contributes to 
hypercapnia (127), dyspnea (128, 129), nocturnal oxygen desaturation (130), and 
reduced exercise performance (131).  
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1.3 Assessment of exercise capacity 
Exercise tolerance (or intolerance) can reflect the level of disability. Exercise tests 
can be used to measure exercise capacity and can be grouped into diagnostic tests and 
field tests.  
 
Cardiopulmonary exercise test (CPET) 
The CPET is recommended as the gold standard for evaluating cardiorespiratory 
fitness in patients with COPD (103). The test is based on the principles that system 
failure occurs when the cardiovascular system, the pulmonary system and/or the 
muscles are under stress. CPET can provide an objective measurement of exercise 
capacity, identify the mechanisms limiting exercise tolerance and evaluate effects of 
interventions (103). The symptom-limited CPET is an incremental test, and is usually 
performed on treadmill or cycle-ergometer. To measure the patients’ endurance 
capacity a constant-load cycle or treadmill test can be used instead of incremental 
CPET. Comparisons between these two tests have indicated that the incremental 
CPET is suitable to describe system abnormalities, but less suitable than the constant-
load endurance test to discriminate improved exercise capacity after interventions (93, 
103). 
 
Timed walk tests 
The field tests consist mostly of walk tests like six-minute walk test (6MWT) (132), 
incremental shuttle walk test (ISWT) (133) and endurance shuttle walk test (ESWT) 
(134). 
6MWT is the most commonly used walk test and the distance walked (6MWD) is the 
main outcome. Oxygen saturation is measured with pulse oximetry (SpO2), and 
perception of dyspnea is registered at rest and at the end of the test (135). The 
 33 
minimal clinical important difference (MCID) for COPD has been reported to be 54 
m (136), while in recently published studies lower MCID values have been reported, 
varying between 25 to 35 m (137). In a recently published review a MCID of 30 m is 
suggested (137). A detailed guideline for test performance of the 6MWT was given in 
2002 (135), but the knowledge about performing and interpretation of the 6MWT has 
increased and a new technical standard was published in 2014 (138).   
The ISWT (133) and ESWT (134) are externally paced tests performed over a 10 m 
course. Paced tests are more standardized than 6MWT since the walking speed is set. 
ISWT is a symptom-limited maximal exercise capacity test; the walking speed is 
increased during the test until the maximum exercise level is reached. ESWT is a 
constant walking speed test, and the speed is based on the results from ISWT, and 
cannot be conducted without first having completed an ISWT.  
 
1.4 Longitudinal changes in lung function and exercise 
capacity 
The longitudinal decline in FEV1 in COPD is higher than normal, but is highly 
variable. Persistent smoking is the most important predictor for the reduction in FEV1 
with an additional effect of exacerbations (15, 16). 
The natural long-term changes in 6MWD in COPD patients, not recruited through a 
pulmonary rehabilitation program or assessment for surgery, with follow-up times 
between one and five years, have demonstrated an annual decline that varied between 
2 and 40 m per year (17-19, 139). 
Studies of longitudinal changes in peak oxygen uptake (V̇O2peak), peak ventilatory 
capacity (V̇Epeak) and breathing pattern are scarce. However, a reduction in V̇O2peak in 
male COPD patients over five years was seen (140). This reduction was related to 
reduction in maximal tidal volume (VTmax) and V̇Epeak. The decrease in V̇O2peak was no 
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less rapid than the decrease in FEV1. We are not aware of any previous studies 
specifically addressing longitudinal changes in breathing pattern.  
 
1.5 Search strategies 
Structured literature searches have been done regularly since October 2011. The last 
search was on February 15th 2015. Papers published after this date are not discussed 
in the thesis. Searches have been performed in Medline, Embase, Cochrane and Ovid, 




The objectives of this thesis were to characterize the breathing pattern during 
incremental exercise in patients having COPD and to examine longitudinal changes in 
exercise capacity and breathing pattern as well as potential predictors for the changes. 
This was accomplished by three separate studies.  
 
Study I 
The aim of this study was to examine predictors for the longitudinal change in the 
6MWD. We hypothesized that high habitual physical activity is associated with a 
lower longitudinal decline in 6MWD, and included self-reported physical activity, 
lung function, smoking habits, body composition, exacerbations and comorbidity in 
the analysis. 
Study II 
The aim of this cross-sectional study was to examine whether a quadratic model could 
satisfactorily describe the relationship between V̇E and VT during exercise in COPD 
patients. The hypothesis was that the curve parameters of the quadratic model which 
describe the breathing pattern were related to FEV1, IRV, and dynamic hyperinflation. 
Study III 
The aims of this study were to examine changes in exercise and ventilatory capacity 
and breathing pattern over four years in a group of COPD patients, and to examine the 
relationship with variables that potentially contribute to explain the changes. We 
hypothesized that V̇O2peak and V̇Epeak would deteriorate during the observation period, 
that breathing pattern would be shallower with a lower VTmax, and that the changes 
were related to lung hyperinflation and airway obstruction.  
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3. Material and methods 
3.1 Design and participants 
The three studies were based of patients with COPD. An overview of the study 
population, timeline and patients included is presented in Figure 3. The patients were 
recruited from the Bergen COPD Cohort Study (BCCS) (141). 
 
Figure 3. An overview of the study population, timeline and patients included in the 
three studies.  
COPD: Chronic Obstructive Pulmonary Disease; BCCS: Bergen COPD Cohort Study; 6MWT: Six-
Minute Walk Test; CPET: Cardiopulmonary Exercise Test 
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The BCCS patients were recruited through outpatient clinics from several hospitals in 
Western Norway and from three private specialist practices in Bergen, Norway (141).  
An overview of the study designs, number of patients, gender, baseline age and 
GOLD stages at baseline for each of the studies are shown in Table 2. 
 
Table 2. Overview of designs, participants, gender, age and GOLD- 2007 (1) stages 
in the three studies 





Age at baseline; 
mean (SD) year 
I Cohort study, 
longitudinal 
with a three year 
follow- up 
389 153/236 64 (7)  GOLD II:  179 (46) 
GOLD III: 169 (43) 
GOLD IV:   41 (11) 
       
II Cross-sectional 
study 
63 28/35 66 (6)  GOLD II:  32 (51) 
GOLD III: 23 (36) 
GOLD IV:   8 (13) 
       
III Cohort study, 
longitudinal 
with a mean 4.5 
years follow-up 
63 28/35 61 (6)  GOLD II:  34 (54) 
GOLD III: 26 (41) 
GOLD IV:   3 (5) 
SD: Standard Deviation; GOLD: Global Initiative for Chronic Obstructive Lung Disease 
 
Patient inclusion and exclusion criteria in BCCS 
Eligible for inclusion in the BCCS were patients having a clinical diagnosis of COPD 
in GOLD stage II-IV, smoking history  ≥ 10 pack years, a post-bronchodilation FEV1/ 
FVC ratio < 0.7 and a post-bronchodilation  FEV1 < 80 % of predicted value 
according to the Norwegian reference values (22). Exacerbations requiring medical 
treatment within the last four weeks prior to inclusion led to postponement of the 
visit. Inflammatory disorders, either self-reported or available from the hospital 
journal, such as rheumatoid arthritis, systemic lupus erythematosus or other 
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connective tissue disorders, inflammatory bowel disease and any active cancer in the 
last five years were causes for exclusion. Common chronic diseases with known 
inflammatory components such as chronic heart disease, diabetes and hypertension 
were not causes for exclusion. The inclusion and exclusion criteria in the three studies 
were the same as in BCCS. 
 
Study I 
Of the 433 patients with clinically stable COPD who met for the first visit in BCCS, 
eleven did not meet the inclusion criteria, five did not want to participate in the study 
and 28 were disabled. Thus 389 patients performed 6MWT at baseline (2006-2007) 
and were included and followed for three years in this study (2006-2010). After 1-
year 319 (82 %) patients and after 3-years 264 (68 %) patients completed the 6MWT. 
Of the patients who were lost to follow-up at 1-year, 11 had died and 59 had 
withdrawn from the study, and at 3-years further 55 patients were lost to follow-up, 
10 had died and 45 had withdrawn. The withdrawn patients were deceased or 
disabled. 
 
Study II and III 
Eighty-nine of the BCCS patients participated in a pulmonary rehabilitation program 
during the first two years of follow-up in 2006-2008. Before start of the rehabilitation 
program, these patients performed a CPET on treadmill. They were invited to a 
second CPET in 2011/2012. At that time 26 of the 89 patients were deceased or 
disabled. The 63 remaining patients performed a second CPET with an intervening 
time between the tests of mean 4.5 years. The data from the second CPET were used 
in Study II (cross-sectional) and in Study III (longitudinal) the data from both CPETs 
were used. In addition to the exclusion criteria in BCCS, patients were excluded from 
performing the CPETs if the partial pressure of oxygen in blood was less than 8 kPa 
at rest.  
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3.2 Ethical considerations  
The patients were given written and oral information when invited to take part in the 
BCCS, and informed that participation was entirely voluntary. At any time of the 
follow-up period they could withdraw from the study without giving any reasons. The 
BCCS was approved by the Western Norway Regional Committee for Medical and 
Health Research Ethics (REK 165.08). The recommendations from the Helsinki 
declaration were followed.  
 
Persons having COPD are struggling with a progressive disease causing 
comorbidities, loss of exercise capacity, and reduced participation in activities of 
daily living. During the visits in BCCS the participants performed a lot of tests, and 
each visit lasted for some hours. It was therefore important to take care of the patients 
by providing necessary rest between the tests, as well as food and beverages when 
required.  
 
The first CPET was performed before start of the pulmonary rehabilitation program 
during the first two years of enrolment in BCCS, and was therefore not synchronized 
with the visits in BCCS, resulting in a less comprehensive test program compared to 
the other visits. On the other hand, the second CPET in 2011/2012 was performed at 
the same time as one of the follow-up in BCCS. We were aware that the total number 
of tests including the CPET could be strenuous for the patients, and therefore ensured 
that sufficient rest where included in the test program. At least one hour and 
maximum two hours before the CPET, the patients were served food. The well-being 
of the patients was a main concern, and the test was stopped if the patients showed 
any form of discomfort. 
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3.3 Outcome measures and assessment tools 
An overview of the assessments tools used in the three studies is given in Table 3. 
The 6MWT, the CPET, lung function testing, measurement of dyspnea and self-
reported physical activity are presented in more detail. 
Table 3. Assessment tools used in the three studies 
Assessment tool 
Study 
I II III 
6MWT x   
CPET  x x 
Spirometry:    
FEV1 x x x 
FVC x x x 
Borg dyspnea score x x x 
mMRC dyspnea scale x   
Body composition:    
BMI x  x 
FMI x   
FFMI x   
Self-reported physical activity x  x 
Charlson index for comorbidities x   
6MWT: Six-minute walk test; CPET: Cardiopulmonary Exercise Test; FEV1:  
Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; mMRC:  
 
3.3.1 Exercise capacity: 6MWT and CPET 
6MWT 
The 6MWT is a widely used field test for evaluating functional exercise performance 
in patients with COPD (14, 103). In Study I all patients in BCCS were assessed with 
modified Medical Research Council; BMI: Body Mass Index; FMI: Fat Mass Index; 
FFMI: Fat Free Mass Index 
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6MWT, except those who were disabled. The test was performed according 
to the ATS guidelines (135) in a 30 m flat, straight enclosed corridor. A trained 
technician supervised the patients, and the patients were asked not to talk 
during the test unless they had a problem. According to safety criteria, the test was 
immediately stopped if the patients had chest pain, intolerable dyspnea, leg cramps, 
diaphoresis, started staggering and pale or ashen appearance (135). None of the 
patients were stopped due to adverse events. The 6MWD was used as primary 
outcome. SpO2 and HR were measured at the start and at the end of the test using 
pulse oximetry (NONIN Medical Inc., Plymouth, MN). The Borg dyspnea score 
(Borg CR10) (142-144) was used to measure the patients level of dyspnea and fatigue 
at the beginning and at the end of the test. The test was performed once each time, 
and a practice 6MWT was not done. Of the 389 included patients at baseline, 13 % 
used supplemental oxygen during the 6MWT, and at one and three years follow-up, 
11of 319 (3 %) and 10 of 264 (4 %) patients, respectively, did so. 
 
CPET 
The CPET is considered the gold standard for evaluating causes of exercise 
intolerance in patients with COPD (103). Exercise intolerance in COPD can be due to 
abnormal oxygen delivery, ventilatory limitation, pulmonary gas exchange 
abnormalities, muscle metabolic dysfunction, deconditioning and symptoms like 
dyspnea and leg effort (103). The CPET can also be used for evaluating the effect of 
interventions for example exercise-based pulmonary rehabilitation, oxygen 
supplementation and drug therapies. In Study II and III the CPET was used to 
evaluate exercise capacity and the test was performed on a treadmill under 
supervisions of experienced technicians (Woodway, model: PPS 55 med Weiss, Weil 
am Rhein, Germany). The CPET was incremental and the patients walked or ran until 
they reached their symptom-limited maximum. The exercise protocol was a modified 
Bruce protocol (145, 146), and started with rest in standing position for 2 minutes. 
The warm-up phase is lasting for 1 minute with a walking speed of 1.5 km·h-1. The 
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test consists of 20 stages, all lasting for one minute. The first stage in the test is at 1.5 
km/h with an inclination of 0 %. In stage 2, the speed is the same as in stage 1 with an 
inclination of 5 %. From stage 3-5, the speed is increasing with 0.6 km/h and the 
inclination is 9, 10 and 11 %, respectively. From stage 6-13, the speed increases with 
0.6-0.7 km/h and the inclination with 1 %. From stage 13-14, the speed increases with 
0.4 km/h, and the inclination increase 1 %. Finally, from stage 15-20, the speed is 
increasing with 1 km/h each minute and the inclination was the same as in stage 14.  
Blood pressure, electrocardiogram (GE healthcare, Cardio Soft EKG, Freiburg, 
Germany) and pulse oximetry were monitored at rest, continuously during the test and 
for 3 minutes into the recovery phase. A tight fitting oronasal mask was adjusted to 
each patient and checked for leaks before starting the exercise. The integrated 
exercise testing system (Care Fusion, Vmax Spectra 229, Hochberg, Germany), was 
calibrated every morning and immediately before each test. The VT, breathing 
frequency (Bf), V̇O2, carbon dioxide production (V̇CO2) and HR were measured on a 
breath by breath basis and averaged over 20 second intervals. V̇E and VT were 
corrected to the body temperature pressure saturated (BTPS) condition, and V̇O2 and 
V̇CO2 to the standard temperature pressure (STPD) condition. The patients graded 
their level of dyspnea and leg discomfort by the Borg CR10 Scale (142, 143).  
In order to measure dynamic hyperinflation during exercise, serial measurements of 
inspiratory capacity (IC) were performed. IC is the volume air that can be inspired 
after a normal expiration, and dynamic hyperinflation is described as the decrease in 
IC from rest to peak exercise (96). A decrease in IC means an increase in EELV of an 
equal volume (147). Low resting IC reflects severe lung hyperinflation (9). 
Measurements of IC were taken at rest, every second minute during exercise and at 
peak exercise. The change in IC (ΔIC) during each of the CPETs was calculated as IC 
at rest minus IC at peak exercise.  
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3.3.2 Lung function testing 
All lung function measurements were performed by trained study personnel according 
to ATS/ERS Standardization of Lung Function Testing (148). Spirometry was 
performed both pre- and post-inhalation of 0.4 mg salbutamol on a Viasys 
Masterscope (Viasys, Hoechberg, Germany). Spirometer calibration was done before 
each test with a 3-L calibration syringe. The FEV1 and FVC were taken as the highest 
values from at least three satisfactory manoeuvres. Post-bronchodilator FEV1 was 
based on Norwegian reference values (22). Spirometry was measured in all the 
included patients in Study I, II and III.  
 
3.3.3 Assessment of dyspnea 
We used two different scales to measure dyspnea. The Norwegian version of the Borg 
CR10 scale (142-144) (Appendix A) was used to measure perceived breathlessness 
during 6MWT (Study I) and both breathlessness and leg discomfort during the CPET 
(Study II and III). A comprehensive explanation of the scale was given to the patients, 
and they either gave verbal response or pointed at the scale to express the self-
experienced sensation to dyspnea or leg discomfort.  
The second scale that was used was the Norwegian version of the 5-point modified 
Medical Research Council (mMRC dyspnea scale) (149), which is a standardised self-
administered grading system to assess the patient’s level of dyspnea in activities of 
daily life. The mMRC was used in Study I (Appendix B).  
 
3.3.4 Self-reported physical activity 
To measure physical activity a questionnaire was used with two questions related to 
spare time physical activity, one for hard and one for light physical activity. The 
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delineation between the two questions was whether the activity resulted in 
breathlessness and sweating or not. The response categories for both questions were 
none, less than 1 hour per week, 1-2 hours per week or 3 or more hours per week. 
These questions have been tested for validity (150, 151) and were used in a large 
Norwegian general population study (152). The physical activity questions were used 
in Study I and III. 
 
3.4 Data processing and statistical analyses 
Data processing 
The data analyses were performed using IBM SPSS Statistics version 20 and 21 
(SPSS Inc. Chicago, Illinois, USA), and are presented in the respective papers. P-
values less than 0.05 were considered statistically significant. 
Descriptive analyses 
Normally distributed data were presented as mean ± standard deviation (SD). Normal 
distribution was assessed by histogram, Q-Q-plots, and Shapiro Wilks test. 
In the three studies, descriptive statistics were used to characterize the study 
population (mean, SD, median and percent). In Study I and II independent samples t-
tests and Persons chi-square tests were used to compare continuous and categorical 
variables, respectively, across gender. In Study III the independent samples t-test was 
used to compare the patients who completed one CPET with those who completed 
two tests.   
Regression analyses 
An overview of the regression analyses used in the three studies is shown in Table 4. 
In the studies, estimated regression coefficients were presented with 95 % confidence 
intervals (CI). 
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Table 4. An overview over the variables and statistical analyses used in the studies 
Study  Variables  Regression 
analyses Outcome Explanatory 






 Self- reported physical 
activity 
 Age, gender, FEV1, FVC, FMI, 
FFMI, Time, number of 
exacerbations, pack years, 
Charlson comorbidity index, self-
reported physical activity 
 
 Participation in pulmonary 
rehabilitation, gender, age, FEV1, 
FVC, FMI, FFMI, pack years, 
exacerbations,  Charlson 
comorbidity index  











      




 Curve parameters 





 Age, gender, height, weight, FEV1, 
FVC, IRV, ΔICadj 
  Quadratic 
regression (VT = 
a + b·V̇E + c·V̇E2) 
 
 Bivariate and 
multivariate 
linear regression 
      












 The change in the curve 
parameters 
a, b and c (CPET2 
minus CPET1) 
 Age, gender, height, baseline 
V̇O2peak or baseline V̇Epeak, smoking 
during follow-up, ΔFEV1, ΔFVC, 
Δweight, ΔICrest, ΔICdynamic, self-
reported physical activity, 







 Age, gender, height, Δweight, 
ΔFEV1, ΔIRV, ΔICrest and 
ΔICdynamic 









regression (VT = 
a + b·V̇E + c·V̇E2) 
 




6MWD: Six-Minute Walking Distance; FEV1: Forced Expiratory Volume in one second; FVC: 
Forced Vital Capacity; FMI: Fat Mass Index; FFMI: Fat Free Mass Index; VT: Tidal volume; V̇E: 
Minute Ventilation; IRV: Inspiratory Reserve Volume; CPET: Cardiopulmonary Exercise Test; 
ΔICadj.: IC at rest minus IC at the end of the CPET adjusted for resting IC; V̇O2peak: peak oxygen 
uptake; ΔV̇O2peak: V̇O2peak at CPET2 minus V̇O2peak at CPET1; ΔV̇Epeak: V̇Epeak at CPET2 minus V̇Epeak 
at CPET1; ΔICdynamic: The change in ΔIC (IC at rest minus IC at peak exercise) at CPET2 minus ΔIC 
at CPET1.  
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In Study I generalized estimating equations (GEE) regression analyses with robust 
standard errors were used to analyze the longitudinal change in 6MWD per year and 
to identify potential predictors for the change. An unstructured working correlation 
structure was applied to adjust for within correlation. In Study I logistic regression 
analyses were applied to assess predictors for physical activity at three years follow-
up.  
In Study III bivariate and multivariate regression analyses were used to analyze the 
relationship between longitudinal changes in oxygen uptake or ventilation and the 
following potential predictors: age, gender, height, baseline V̇O2peak or V̇Epeak, 
smoking during follow-up, ΔFEV1, ΔFVC, Δweight, ΔICrest and ΔICdynamic, self-
reported physical activity, exacerbations and time between the tests. 
 
Quadratic model 
In Study II and III a quadratic model (VT = a + b·V̇E + c·V̇E2) was used to describe the 
breathing pattern in terms of the relationship between V̇E and VT for each individual. 
Bivariate and multivariate regression analyses were used to analyze the relationship 
between the curve parameters a, b and c, and possible explanatory variables such as 
age, gender and height (Study II and III). Additional explanatory variables in Study II 
were weight, FEV1, FVC, IRV and ΔICadj. (IC in rest minus IC at the end of the CPET 
adjusted for resting IC), and in study III: Δweight, ΔFEV1, ΔFVC, ΔICrest and 
ΔICdynamic. Δweight, ΔFEV1, ΔFVC and ΔICrest were calculated as the value at CPET2 
minus the value CPET1. ΔICdynamic was calculated as the change in ΔIC (IC at rest 
minus IC at peak exercise) at CPET2 minus ΔIC at CPET1.  
The VTmax and V̇E at VTmax were calculated from the individual quadratic relationships.  
The VTmax was the point where the first derivative of the quadratic equation was zero 
(Figure 4);  
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VT = a+ b·V̇E + c·V̇E2 
VTmax = a + b ∙ (-b/2c) + c ∙ (-b/2c) 2 
   
Figure 4. The V̇E – VT relationship in one of the patients illustrating the quadratic 
relationship and the position of VTmax and V̇E at VTmax.  
 
Sample size calculation  
Sample size calculation was done prior to study start in BCCS with FEV1 as the main 
outcome, and this calculation was basis for the number of patients included in Study I. 
With a power of 80 % and alpha-level set to 0.05, the study had included enough 
patients (433 patients) to detect minimal clinical important differences in FEV1 when 
the within subject SD was 200 mL·year-1 and the SD of the rate of decline in FEV1 
was 30 mL·year-1.  
Sample size calculation was also performed for Study II and III to assess whether the 
available number of observations would render results with acceptable precision 
(153). With an estimated change in mean V̇O2peak of 10 %, power of 80 %, alpha of 
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0.05 and a SD of 20 % the calculations showed that 31 patients had to be included. A 
change in V̇O2peak of 10 % was considered as a clinically important change.  
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4. Summary of results 
In this chapter, a condensed summary of the results from Study I, II and III is 
presented. 
4.1 Paper I  
Physical activity and longitudinal change in 6-min walk distance in patients with 
COPD  
Frisk B, Espehaug B, Hardie JA, Strand LI, Moe-Nilssen R, Eagan TM, Bakke PS, 
Thorsen E. Respir Med. 2014 Jan;108(1):86-94.  
The aim of the study was to examine predictors for the longitudinal change in 
6MWD.  
The follow-up time was three years with measurements at baseline and at one and 
three years. Data on 389 patients with COPD were available at baseline, and 319 (82 
%) and 264 (68 %) completed the 6MWT at year one and three, respectively. The 
mean age was 64 ± 6 years, 236 (61 %) were men, and the patients were in GOLD 
stages II-IV. During the first two years of follow-up, 89 of the 389 patients were 
enrolled in a 7-week pulmonary rehabilitation program. There were no significant 
differences in baseline characteristics between the participants in the rehabilitation 
group and the other participants. 
The main findings were that the patients regardless of GOLD stages maintained the 
6MWD after one year, while after three years it was significantly decreased in GOLD 
stage III (p=0.009) and IV (p=0.007). Baseline predictors for these changes were 
self-reported hard physical activity and FEV1. With a reduced FEV1 the reduction in 
6MWD was higher, and patients who reported that they performed regular hard 
physical activity had less reduction in 6MWD. The level of physical activity was 
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higher after three years in patients who had participated in pulmonary rehabilitation 
during the observation period with an odds ratio of 2.4 (95 % CI 1.4−4.2, p = 0.001). 
 
4.2 Paper II 
Airway obstruction, dynamic hyperinflation, and breathing pattern during 
incremental exercise in patients with COPD  
Frisk B, Espehaug B, Hardie JA, Strand LI, Moe-Nilssen R, Eagan TM, Bakke PS, 
Thorsen E. Physiol Rep. 2014 Feb 7;2(2):e00222. Doi: 10: 1002/phy2.222. 
The aim of the study was to examine whether a quadratic model (VT = a + b·V̇E + c· 
V̇E2) could satisfactorily describe the relationship between V̇E and VT during exercise 
in patients with COPD.  
In this cross-sectional study, 63 patients, mean age 66 ± 6 years, 35 (56 %) men, 
performed an incremental exercise test on treadmill. The patients were airflow limited 
with a FEV1 of 48 % (SD=15 %) of the predicted value. 
The quadratic model could be used to describe the relationship between V̇E and VT in 
59 of the 63 patients. For these patients the p-value of the F-statistic for the quadratic 
model was < 0.05 and the median R2 was 0.90 (range 0.40 to 0.98). The remaining 
four patients were excluded from further analyses, because the goodness of fit was not 
statistically significant. These patients had a short exercise time and thereby few data 
available for computing a regression curve.  
The multivariate linear regression analyses showed that the linear coefficient (b) was 
negatively (p=0.001) and the quadratic coefficient (c) positively (p<0.001) related 
to FEV1. Age, gender, height, weight, FVC, IRV and ΔICadj were not associated with 
the curve parameters after adjusting for FEV1. With a lower FEV1, maximal VT was 
lower and achieved at a lower V̇E. 
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In the multivariate regression analyses both VTmax and V̇E at VTmax were related to 
FEV1 (p<0.001), but not to age, gender, height, weight, FVC and ΔIC. 
 
4.3 Paper III 
Peak oxygen uptake and breathing pattern in patients with COPD – a four year 
longitudinal study  
Frisk B, Hardie JA, Espehaug B, Strand LI, Moe-Nilssen R, Eagan TM, Bakke PS, 
Thorsen E. (2015): Submitted. 
The aims of the study were to examine longitudinal changes in V̇O2peak, V̇Epeak and 
breathing pattern over four years in a group of patients with COPD, and to examine 
potential predictors of change.  
During the first two years of follow-up in BCCS (2006-2008), 89 patients were 
enrolled in a 7-week pulmonary rehabilitation program. The patients performed a 
CPET, before start of the rehabilitation program. These patients were invited to a 
second CPET in 2011-2012. Sixty-three of the 89 patients performed the second 
CPET. The remaining 26 patients were deceased or disabled. The 63 included patients 
were in GOLD stages II-IV, the mean age was 61 ± 6 years and 35 (56 %) were 
males. FEV1 was 51 ± 14 % of predicted values.  
Exercise capacity measured as V̇O2peak and V̇O2peak/kg and ventilatory capacity 
measured as V̇Epeak deteriorated significantly (p<0.001) during the intervening time of 
4.5 years. The reduction in V̇O2peak was larger with a higher baseline V̇O2peak 
(p<0.001) and with a larger reduction in ΔICrest (p=0.002) and ΔFEV1 (p=0.031). 
Smoking and age predicted the change in V̇O2peak as well. The reduction in V̇Epeak was 
larger with a larger reduction in ΔICrest (p=0.005) and ΔFEV1 (p=0.031). A higher 
baseline V̇Epeak predicted a larger reduction in V̇Epeak (p=0.002). 
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The quadratic model was used to describe the relationship between V̇E and VT at 
CPET1 and CPET2. At CPET1 the quadratic model could be used in 61 of 63 
patients, and in 59 of 63 at the second test. The coefficients in the equations; the 
estimated constant (a), the linear coefficient (b) and the quadratic coefficient (c) 
changed significantly from CPET1 to CPET2. The linear coefficient (b) increased 
(p=0.007) and the quadratic coefficient (c) decreased (p=0.002). Maximal VT was 
achieved at a lower VE at CPET2. ΔFEV1 predicted the changes in the curve 












In the first section methodological considerations are discussed, whereas the main 
objectives of the thesis and results of the three studies are discussed in the second 
part.  
5.1 Methodological considerations 
5.1.1 Study design and study population 
The participants in the studies were subsamples from the BCCS, all diagnosed with 
COPD. Study I and III were observational longitudinal studies with follow-up times 
of 3 and 4.5 years, respectively, while Study II was a cross-sectional study. Cohort 
studies can be categorized as prospective, retrospective or cross-sectional (154). Of 
these designs, it is only the prospective cohort study that can be characterized as a 
longitudinal study, and is designed to analyse the longitudinal development of definite 
characteristics over time (155). The research question addresses whether baseline 
characteristics can predict the change in an outcome variable, or the change in an 
outcome variable is associated with the change in one or more possible predictor 
variables (154). A cohort study comprises persons with a common characteristic, for 
example regarding exposure or ethnic identity, and can consist of an exposed and an 
unexposed group. The exposed participants are compared to the unexposed control 
group in terms of occurrence of the outcome. The main advantage of prospective 
cohort studies compared to cross-sectional studies is that the change in an outcome 
variable can be studied over time and analysed with respect to the development in 
individual explanatory variables (154, 155)  An advantage of Study I and III was the 
longitudinal design with rather long follow-up times of 3 and 4.5 years.  
COPD is a progressive disease, and with increased disease severity the loss to follow-
up is a natural consequence. The dropout rate of the 389 patients in Study I from 
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baseline to three years was 32 % and in Study III for the 89 patients at CPET1 with a 
mean follow-up time of 4.5 years was 29 %. The patients were mainly lost to follow-
up because of death or increased disease severity. The dropout rate in Study I was in 
accordance with previous studies (17, 19, 139), while for Study III the only 
comparable study had a dropout rate of 51 % (140) being higher than in our study. An 
advantage with Study I was the large sample size with 6MWD data that allowed for 
analyses of subgroups, for example to examine the impact of disease severity 
according to GOLD stages. 
Two CPETs were performed in Study III. The CPET aims to measure maximal 
exercise capacity and is a very exhausting test, where the persons are pushed to their 
limit of exercise tolerance. In the present study 71 % of patients performed two 
CPETs over a time interval of 4.5 years. However, a sample size of 63 patients is still 
small in multivariate linear regression analyses and restricted the number of 
explanatory variables that could be included in the analyses. The number of 
explanatory variables included in our multivariate regression analyses was five to 
seven.  
In the BCCS a control group without COPD and a group with COPD were included. 
The control group did, however, not perform the 6MWT, and since 6MWD was the 
main outcome variable in Study I, a comparison between the two groups was not 
possible. The 6MWT has been developed to assess functional capacity targeted at 
people with at least moderately severe impairment (135). In healthy individuals and in 
patients with mild COPD the 6MWD is usually biomechanically limited by their 
maximal walking speed rather than by their ventilatory capacity. Our main focus was 
on examining the individual COPD patient’s longitudinal development in relation to 
progression of the disease severity, exercise capacity and breathing pattern, and not to 
examine the relationship or difference in 6MWD change between healthy people and 
COPD patients.  
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In Study II a cross-sectional design was used. The data were collected at one point in 
time. This design is appropriate to describe a phenomenon or an outcome and factors 
that may be associated with the outcome (154).  
 
5.1.2 Internal validity 
Internal validity can be defined as the validity of inferences drawn pertaining to the 
population being studied (154). Two types of errors are of main concern in the study 
design; systematic error (bias) and random error. Systematic errors have to be dealt 
with when designing the study and the most common systematic errors are selection 
bias, information bias and confounding. 
 
Selection bias 
Selection bias can occur in the recruitment process, and from factors influencing the 
study population (154). There can be a selection bias when the exposure and outcome 
for the recruited participants in the study differ from the population who theoretically 
could have been eligible for the study. The BCCS recruited patients through 
outpatient clinics from several hospitals in Western Norway and from three private 
specialist practices in Bergen Norway (141). Participation was voluntary, and during 
the observation period the visits were conducted at the hospital, which meant that the 
participants had to manage to meet at the hospital. COPD patients are often limited in 
performing activities of daily living, and the most severely ill patients were supposed 
not to take part in the study because of reduced functional capacity. In Study I there 
were few patients with serious disease as represented by GOLD stage IV. Inclusion of 
seriously ill subjects at baseline will increase the drop-out rate during the observation 
period. In Study I 11 % of the patients were in GOLD IV at baseline.  
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We assume that the sample assessed at baseline in Study I was representative for the 
common COPD population, except those with mild disease in GOLD stage I. In Study 
II and III the recruited patients were a subsample of those included in Study I. They 
had participated in pulmonary rehabilitation during the first two years of follow-up in 
BCCS and could therefore have been biased to have higher functional capacity than 
the common COPD population. However, when comparing the patients included in 
Study I there were no significant differences in baseline characteristics between those 
who participated in pulmonary rehabilitation and the non-participants. According to 
GOLD stages 49 % of the 63 patients in Study II and 46 % in Study III were in 
GOLD stages III and IV. The distribution of the patients with respect to disease 
severity was thus almost the same as in Study I. However, only three of the 63 
patients who performed the first CPET were in GOLD stage IV, and at the second 
CPET eight were in GOLD stage IV. It is therefore likely that the most severely ill 
patients were not represented. 
 
Information bias 
Information bias can result from measurement errors or misclassification (154). If the 
variable is measured on a categorical scale and the study subject is placed in an 
incorrect category this leads to misclassification. It is conceivable that participants 
could have been misdiagnosed with COPD, but at baseline visit in the BCCS the 
participants went through extensive examinations, and a possible misclassification 
should then have been detected.  
The studies are based on information and measurements collected prospectively, and 
recall bias could therefore be minimized. In study I and III a self-reported 
questionnaire about physical activity level was used. The patients should report 
habitual physical activity for an average week, and there can be a possibility for 
occurrence of recall bias. It seems more likely that the reported activity level was 
biased by an overestimation, and thereby a misclassification of patients regarding 
 57 
activity level could occur. Another possible misclassification for all three studies 
could be that the smokers underreported their smoking habits and thereby influenced 
the calculation of pack years. The smoking habits were registered by the physician at 
each visit, not by questionnaire. In BCCS a detailed registration about smoking habits 
were done at baseline and at follow-up; whether the subjects were ex- or current 
smoker as well as the total smoking load. It is demonstrated that the more detailed 
information registered on smoking habits, the less bias (154). If smoking is due to an 




Confounding can be defined as the confusion or mixing of effects (154). A 
confounder is a third variable, an unobserved exposure, that is associated with the 
exposure and the outcome variable, and can act as a cause or a proxy for the outcome 
(154). 
Three methods are described to prevent confounding (154). The first concerns 
randomization to an experimental or a control group, but in cohort studies, 
randomization is not applicable. The second method is matching, which is an 
effective way to prevent confounding in cohort studies. The third method concerning 
restriction, involves selecting subjects for a study in which all have the same or 
almost the same value for a variable that otherwise could be a confounding factor. 
Tobacco smoking is the primary cause for COPD, and if we had included never 
smokers as well as smokers in the study, smoking could be a confounder. Therefore, 
one of the inclusion criteria in BCCS was that all participants had a smoking history 
of ≥ 10 pack years.  There are statistical methods that adjust for possible confounding 
like stratification, regression, matching, standardization, propensity score analyses, 




Random error can be described as the variability in data that cannot easily be 
explained (154). The main sources of random errors are lack of precision in the 
measurements (low repeatability), and insufficient sample size. One way of dealing 
with the latter is to include a large sample size. The precision of estimation can 
thereby be improved.   
Study I has a relatively large sample size, and the precision of the estimate for the 
change in 6MWD from baseline to three years,  given by the CI was -34 to -12 m.  For 
Study II and III sample size calculation was done prior to study start. The calculation 
was based on a coefficient of variation in V̇O2peak of 5 %, and a clinically significant 
difference of 10 %.  With statistical power of 80 %, alpha of 0.05, and a SD of 20 %, 
31 patients were then sufficient. However, even though enough patients were 
included according to the sample size calculation, the estimation process can be 
comparatively more precise with a larger study sample. Less precision and more 
random error occurs in small samples. 
 
5.1.3 External validity 
External validity refers to the generalizability of the results from the study population 
to the target population (154). This implies that the study population must be a 
representative subsample of the target population. The target population for the three 
studies was the common COPD population in Norway. 
Roughly 10 % of the Norwegian population lives in Hordaland County where the 
participants in BCCS were recruited from. The adult sex and age composition of the 
inhabitants in Hordaland is very similar to the overall Norwegian population (156). 
Approximately 10 % of the Norwegian population and the inhabitants in Hordaland 
have been diagnosed with COPD. It is therefore reasonable to believe that the COPD 
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population in Hordaland do not differ from the COPD population in the rest of the 
country. 
Participation in BCCS was voluntary, and since the visits at baseline and at follow-up 
were performed at the hospital, it is likely that most severely ill patients did not accept 
to be included. The distribution according to GOLD stages confirmed this. The 
majority of patients were in GOLD stages II and III, while only a few were in GOLD 
stage IV. However, when performing longitudinal studies with COPD patients, 
recruiting the most severely ill patients will always be a problem.  
 
5.1.4 Reliability 
The reliability of an instrument is the degree of consistency in which the instrument 
measures what it is supposed to measure (157). The less variation an instrument 
produces in repeated measurements of a characteristic, the higher its reliability. 
In the three studies the 6MWT (Study I) and CPET (Study II and III) were used to 
measure exercise capacity. The relationship between  6MWD and V̇O2peak (measured 
on a progressive incremental CPET has shown to be moderate to strong, with 
correlation coefficients ranging from 0.4 to 0.8 (158-166).  
The 6MWT is a well-established self-paced test of walking capacity, with 6MWD as 
the primary outcome (135). The 6MWD is shown to be a reliable measure, with intra 
class correlation coefficient ranging from 0.72 to 0.99 (167-172). It is recommended 
to perform two 6MWTs to reduce the learning effect which is a bias in 6MWD (137). 
The mean distance between two repeated 6MWD in COPD has been reported to be 
between 24-29 meters (170). Because of limited resources, the 6MWT in Study I was 
only performed once at each visit. It is possible that a learning effect could hide a 
natural decline in 6MWD, especially since the patients were shown to increase their 
6MWD from baseline to one year, but it is less likely that the learning effect could 
have lasted for three years.  
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The CPET was performed on a treadmill and a maximal incremental protocol, the 
modified Bruce protocol (145, 146), was used. The protocol is standardised and 
integrated in the exercise testing system. Treadmill exercise testing has some 
advantages compared to cycle ergometer. For most individuals, treadmill walking is a 
more familiar activity than cycling. Walking (or running) on a treadmill requires a 
larger muscle mass and more work against gravity than cycling and leads to a greater 
stress on the organ systems (93). The maximal V̇O2 is reported to be 5-10 % higher on 
treadmill than cycle ergometer (173-176). This may be important for athletes, but less 
important for COPD patients, unless the V̇O2peak is critically low, influencing the 
ability to perform daily activities. More important is to consider if the CPET is used to 
evaluate an effect of any intervention. Then the same exercise modality has to be 
used.  
To ensure reproducibility of the CPETs, it is important to reduce factors that may 
contribute to the variability in measures, like patient motivation, patient instructions, 
time of the day, testing procedures, equipment/calibration errors, change in use of 
medication and changes in the underlying disease process. The integrated testing 
system that we used, was calibrated every morning and immediately before each test. 
At every CPET, one physician and one technician (physiotherapist or bioengineer) 
were responsible that the test was performed according to the standardised procedure. 
During the test, the physician monitored the patients while the technician was 
responsible for the patients’ well-being as well as pushing them to their limit of 
exercise tolerance, and in addition performing measurements of dyspnea and IC 
during the tests. The IC procedure was done as described by O’Donnell and Webb 
(96). However, the methodology of measuring IC during exercise has been developed 
on cycle ergometer. As far as we know reliability testing of IC during treadmill 
testing has not been done. Whether the cut-off point to define dynamic hyperinflation 
as a reduction in IC of 0.4L (84) is the same on treadmill as on cycling is unknown. 
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5.1.5 Statistical methods 
The statistical methods used in the three studies are described in chapter 3.3. In this 
chapter the methods used to analyse the longitudinal data in study I and III will be 
discussed. 
In Study I GEE regression analyses were used to analyse the longitudinal 
development of 6MWD and to identify potential predictors for the change. An 
advantage with this method is that all available data are included in the analyses, 
without summarizing the longitudinal development of each individual into one value. 
Study I had three longitudinal measurements, and patients were lost to follow-up at 
one and three years. To avoid that subjects were excluded from the analyses without 
having a complete dataset, GEE provides an approach for analysing repeated 
measurements.  
Instead of using GEE to account for correlated outcome measures, a mixed effects 
model (multilevel model, random coefficient model) could have been used (155). This 
method is also dealing with the missing data like GEE; meaning that all available data 
can be included in the analyses. Hubbard et al. (177), however, argue that the GEE 
approach is more useful. 
In Study III we also analysed longitudinal data. The measurements were only 
performed twice, and since we had no missing data the relationship between the 
changes in the outcome variables and associations with the changes in potential 
predictor variables could be analysed by using multivariate linear regression analyses. 
To account for a possible regression to the mean effect we included the baseline value 
of the outcome variable in the regression model.  
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5.2 Discussion of the main results 
The overall aims of the thesis were to characterize the breathing pattern during 
incremental exercise in patients having COPD and to examine longitudinal changes in 
exercise capacity and breathing pattern, as well as potential predictors for the 
changes.  
 
5.2.1 Longitudinal changes in exercise capacity  
In Study I and III the longitudinal changes in exercise capacity were examined, and 
the main outcomes were 6MWD in Study I and V̇O2peak in Study III. The 6MWD 
decreased significantly from baseline to three years, but the decrease was only evident 
for patients in GOLD stages III and IV, with 36 m (95 % CI:-51 to -7) and 79 m (95 
% CI:-125 to -20) respectively. These reductions are higher than the 30 m which is 
considered as the minimal clinically important change for 6MWD (137), taking 
measurement error into consideration. Patients in GOLD stage II maintained the 
walking distance during the follow-up. In healthy subjects and in patients with milder 
COPD, the maximal walking speed during the 6MWT may be biomechanically 
limited and not limited by ventilatory capacity. Since only one 6MWT was performed 
at each visit, a learning effect could have hidden a natural decline in 6MWD during 
the first year, but it is unlikely that the effect could last for three years. Our findings 
were consistent with both Casanova et al. (17) and Spruit et al. (19) who 
demonstrated that 6MWD declined over time, but was only significant in patients 
with severe airflow limitation. The patients in our study were a subsample in the 
ECLIPSE study. The finding that the results were consistent with those of Spruit et al. 
(19) was therefore not surprising. In the study of Kapella et al. (139) the 6MWD was 
demonstrated to be stable during a follow-up time over three years, maybe because 
patients with significant comorbidities were excluded from the study and 80 % of the 
study sample was smoke free during the study period. 
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The V̇O2peak deteriorated significantly for the total group during the 4.5 years of 
follow-up with a mean decline of 50 (SD=68) mL·min-1·yr-1. To our knowledge there 
is only one previous study that has examined the natural longitudinal changes in 
exercise capacity and using V̇O2peak as main outcome (140). The follow-up time in 
this study was 5 years with repeated measurements every 6 months. The annual 
decline in V̇O2peak was 32 (SD=60) mL·min-1·yr-1, which is slightly lower compared 
to our results. We performed only to measurements compared with Oga’s 11 (140). 
With only two measurements we were not able to identify short term variability in the 
changes of V̇O2peak during the observation period. In the study of Oga et al. (140) the 
decline in V̇O2peak was shown to be almost linear during the first 2.5 years of follow-
up, while in the next 2.5 years an increased variability was demonstrated at each of 
the visits. The lowest values of V̇O2peak were measured after 2.5 and 4 years. These 
variable changes would not have been detected without the repeated measurements 
every 6 months.   
In Study I a total of three measurements of 6MWD were done. In the GEE regression 
analyses the variable “time” was modelled as both a continuous and as a categorical 
variable (baseline, year 1 and year 3). The results from the first alternative did not 
identify that the 6MWD actually increased from baseline to 1-year, and thereafter 
decreased. The results only demonstrated a decrease in 6MWD from baseline to three 
years. When analysing the data with “time” as a categorical variable an increase in 
6MWD from baseline to 1-year, and a decrease between year 1 and 3 were 
demonstrated.  
In Study I, the findings demonstrated that level of habitual physical activity and FEV1 
at baseline predicted the longitudinal changes in 6MWD. Those who reported 
performing hard physical activity at baseline demonstrated a positive influence on the 
longitudinal change in 6MWD. An additional finding was that the level of physical 
activity was higher at three years follow-up in patients who had participated in a 
pulmonary rehabilitation program during the observation period. These findings 
indicates that performing hard physical activity in terms of being breathless and 
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sweating, influences the long term changes in 6MWD, independent of participation in 
pulmonary rehabilitation or not. The results indicate that hard physical activity is 
important to maintain functional exercise capacity.  
There was a difference in activity level at 3 years follow-up between participants and 
non-participants in pulmonary rehabilitation. Previous studies evaluating the effect of 
pulmonary rehabilitation on physical activity have shown inconsistent results. Some 
demonstrated effect of pulmonary rehabilitation on physical activity (45, 178), 
whereas some failed to do so (179-181). In the studies showing negative effects, the 
lack of improvement in physical activity was observed despite an increased exercise 
capacity and quality of life. Physical activity was measured with devices as step 
counters (pedometers) and activity monitors (accelerometers). These instruments have 
been validated for use in COPD. Some sources of error might, however, have 
influenced the results in these studies such as; underestimating of the steps during 
walking at low speed and inaccurate estimation of energy expenditure especially 
during low speed walking (70).  
A methodological problem with self-reported questionnaire is recall bias, and 
sometimes overestimation. There are limitations with the existing physical activity 
assessment tools both self-reported and monitors that seem to influence the accuracy 
of the registrations, which can lead to inconsistent results (70).  
In Study III physical activity was not assessed synchronized with the second CPET, 
which is a limitation. We assumed that the physical activity level measured at 3 years 
follow-up in Study I was not substantially changed at CPET2 one year later. On this 
basis we did not find that the change in V̇O2peak was related to habitual physical 
activity. 
In Study I we demonstrated that FEV1 at baseline predicted the longitudinal change in 
6MWD over 3 years. In Study III we found that the change in V̇O2peak was associated 
with the change in FEV1 over a period of 4.5 years. The association between 6MWD 
and V̇O2peak on a progressive incremental CPET has been shown to be only moderate 
 65 
to strong (158-166). Ventilatory capacity is reduced in COPD and is related to 
maximal expiratory flow rates. At some point during the disease progression 
ventilatory capacity will be the limiting factor for exercise capacity. Therefore it is 
reasonable to find an association between FEV1 and exercise capacity measured as 
6MWD and V̇O2peak. However, it is important to keep in mind that exercise capacity 
cannot be predicted from physiological variables measured at rest, like FEV1 (103). A 
person’s exercise capacity level can only be determined by actually measuring it.  
In Study III we also found that the change in V̇O2peak was related to the change in IC 
at rest which is a measure of resting lung hyperinflation. Lung hyperinflation is said 
to occur when TLC is greater than 120 % of the predicted value and/or when EELV 
and RV are above 120 to 130 % of the normal predicted value (182). We are not 
aware of any studies having described the longitudinal changes in TLC in COPD 
patients. A limitation with our study was that TLC was not measured, thus it is 
possible that the increase in static hyperinflation is underestimated. Our results 
demonstrated a decrease in IC at rest from CPET1 to CPET2, and we can only 
conclude that a relationship between the change in IC at rest and the change in 
V̇O2peak was found. We did not find that the change in V̇O2peak was related to the 
change in dynamic hyperinflation. Dynamic hyperinflation remained unchanged 
between the two CPETs. TLC is expected to remain unaltered or slightly increased 
during incremental exercise (183-185). However without knowledge about the 
longitudinal change in TLC, changes in dynamic hyperinflation may have been 
obscured.   
 
5.2.2 Breathing pattern during incremental exercise 
In Study II we demonstrated that a quadratic model could satisfactorily describe the 
breathing pattern in terms of the relationship between V̇E and VT during progressive 
incremental exercise in most COPD patients.   
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The relationship between V̇E and VT during incremental exercise has been 
characterized by three phases (91). In the first phase, the relationship between V̇E and 
VT is linear. In the second phase the increase in V̇E is mostly caused by an increase in 
the Bf and with only a smaller increase in VT, while in the third phase, the increase in 
V̇E is caused by an increase in Bf only. At the end of this phase a fall in VT can be 
demonstrated. Various methods have been used to characterize the individual V̇E-VT 
relationship during exercise. The Hey plot (90) describes the slope and intercept in the 
first part of the response up to a VT equal to about half of the vital capacity. Cotes has 
proposed a maximal VT and VT  at a V̇E of 30 L·min-1 (VT30) (94). Neder et al. (186) 
has described the breathing pattern including VT at predefined fractions of peak V̇E in 
healthy subjects. The maximal VT or the plateau of VT and the inflection point are 
described by O’Donnell et al. (9). The inflection point is thought to represent a 
mechanical limit, and after this point a further increase in V̇E can only be 
accomplished by an increase in Bf.  
There are a limitations with the Hey plot (90), VT30 and VTmax (94) and the VT at a 
given fractions of peak V̇E (186) in that all the observed data are not included in the 
analyses. The VT30 (94) requires that a ventilation of minimum 30 L·min-1 is achieved. 
In COPD patients, a maximal V̇E below this value may occur, and the method will 
thereby not be applicable for these patients. 
As described by O’Donnell et al. (9) the inflection point is determined “by eye” by 
two or three persons independently of each other. If less experienced observers are 
determining the inflection point, it can influence the accuracy and can be biased by 
increased variability between the observers. When we examined our exercise data, it 
was not obvious to see where an inflection point occurred. In a quadratic model which 
is analysed mathematically, the curve parameter c in the equation will be related to a 
“perceived” inflection point as it describes the “sharpness” of the curvature, and the 
VTmax can be calculated by derivation of the equation. By using this method 
determination of the physiological parameters will not be influenced by intra-and/or 
inter observer reliability. Another consideration is that during an incremental exercise 
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test, there will be a gradual transition between the phases described by Gallagher et al. 
(91), and determining a cut-off point where the change from one phase to the other 
takes place, is not readily defined. Therefore different choice of cut-off point may 
affect the characteristics of each phase. 
We performed the CPET on treadmill, while in the previous studies that have 
described the breathing pattern cycle ergometry was used. The breathing pattern has 
been demonstrated to be different in treadmill exercise as compared with cycle 
exercise in healthy young subjects (187). The increase in VT with increasing V̇E was 
steeper with cycling compared to running, but the VTmax was not different between the 
two modes of exercise. When the absolute value of the quadratic curve parameter c is 
increased, as with cycle compared to treadmill exercise, the inflection point may be 
easier to define. Since we only performed the CPETs on treadmill, our data cannot 
enlarge upon this issue. Further research is needed.  
In Study II we found that the curve parameters in the quadratic equation were related 
to FEV1. With a lower FEV1, the maximal VT was lower and achieved at a lower V̇E. 
In COPD incomplete expiration leads to accumulation of gas in the lung, and the 
breathing will take place at a lung volume where the time constant allows complete 
respiratory breathing cycles. The airway obstruction, expressed by FEV1, is 
determined by airway diameter, gas density and compliance of the airway wall (79). 
The time constant is the product of resistance and compliance, and FEV1 is 
related to both. A relationship between the curve parameters and FEV1 was therefore 
not surprising. 
In Study III we examined the longitudinal changes in breathing pattern in terms of the 
relationship between V̇E and VT. The breathing pattern changed towards a lower VTmax 
and a lower VT at a given V̇E. Since V̇Emax and V̇O2peak deteriorated during the follow-
up, a reduced VTmax was expected. The changes in the curve parameters were related 




The results are consistent with previous studies demonstrating that exercise capacity 
deteriorates over time in patients with COPD and that the decrease in exercise 
capacity is related to the decrease in lung function. The deleterious effect of persistent 
smoking on exercise was also demonstrated. Optimal treatment to improve lung 
function and smoking cessation programs are established corner stones in the 
treatment of COPD. Our results support the importance of exercise training and 
physical activity in maintaining exercise capacity. Exercise training is an important 
part of all pulmonary rehabilitation programs, but the availability of such programs 
for the patients is still limited and dependent on the priorities of the health authorities. 
It is established that participation in a rehabilitation program improves exercise 
capacity, but less is known about the long-term effects of such programs and 
established guidelines for follow up is lacking. 
 
With respect to the description of breathing pattern with a quadratic equation, there 
are still many unknowns. Breathing pattern is different with different modes of 
exercise, but how breathing pattern relates to dyspnea is largely unknown. So far, our 
description of breathing pattern with a quadratic equation may provide a tool for 





 Exercise capacity for patients in GOLD stage II was maintained when 
measured as 6MWD over 3 years, but was significantly reduced for patients in 
GOLD stages III and IV. The level of habitual physical activity and FEV1 were 
predictors for the longitudinal change in functional capacity.  
 The level of physical activity was higher after three years in subjects who had 
participated in a pulmonary rehabilitation program during the observation 
period. 
 A curvilinear model provides a method to describe a nonlinear breathing 
pattern during incremental exercise in most COPD patients. The breathing 
pattern was related to FEV1.  
 Exercise capacity measured as V̇O2peak deteriorated significantly over 4.5 years. 
The reduction was related to an increase in lung hyperinflation and a reduction 
in FEV1 along with persistent smoking in the observation period.  
 The longitudinal changes in breathing pattern demonstrated a change towards a 
lower VTmax and a lower VT at a given V̇E, and the reduction in FEV1 predicted 
these changes. 
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7. Perspectives  
This thesis has highlighted some aspects regarding longitudinal changes in exercise 
capacity and breathing pattern in patients with COPD. There are, however, still 
questions to be answered. 
Suggestions for further research: 
 To perform reliability testing of the IC measurements when the CPET is 
performed on treadmill. 
 To study the longitudinal development of TLC. 
 To compare the curvilinear model with determination of the inflection point in 
treadmill and cycle ergometer in the same patients, cross-sectionally and 
longitudinal. 
 To examine longitudinal changes and associations between V̇O2peak and 
6MWD when the measurements are performed synchronized in a general 
COPD cohort. 
 To examine the relationship between perceived dyspnea and breathing pattern 
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